Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Argatroban

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    16 result(s) found for: Argatroban. Displaying page 1 of 1.
    EudraCT Number: 2021-001456-34 Sponsor Protocol Number: ArgatrobanECMO_1.2 Start Date*: 2021-07-08
    Sponsor Name:Medical University of Vienna
    Full Title: A prospective randomized pilot trial on safety and feasibility of Argatroban as anticoagulant in patients with extracorporeal membrane oxygenation (ECMO)
    Medical condition: patients requiring treatment with extracorporeal membrane oxygenation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: View results
    EudraCT Number: 2022-002259-20 Sponsor Protocol Number: CASUAL_ECMO Start Date*: 2023-08-17
    Sponsor Name:Medical University of Vienna
    Full Title: A three-arm randomized controlled non-inferiority pilot study Comparing Anticoagulation Strategies using Unfractionated heparin, Argatroban and Low-molecular-weight heparin for Extracorporeal Memb...
    Medical condition: patients with indication for extracorporeal membrane oxygenation therapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-002319-25 Sponsor Protocol Number: Start Date*: 2012-11-19
    Sponsor Name:University of Texas Health Science Center
    Full Title: A pilot, phase IIb, randomised, multicentre trial of Argatroban in combination with recombinant tissue plasminogen activator for acute stroke
    Medical condition: Ischemic Stroke
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-003521-42 Sponsor Protocol Number: ARG-E08 Start Date*: 2017-02-09
    Sponsor Name:Mitsubishi Tanabe Pharma GmbH
    Full Title: SAICoDis – Safety of Argatroban Infusion in Conduction Disturbances. A prospective, open, multicenter safety study to investigate conduction disturbances in patients receiving argatroban therapy.
    Medical condition: Patients without diagnosed HIT II but with a coronary heart disease and with a diagnosed stable or unstable angina are planned for a percutaneous coronary intervention (PCI) according to clinical r...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10003211 Arteriosclerosis coronary artery PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-000042-31 Sponsor Protocol Number: ArgatrobanHDF01 Start Date*: 2008-09-04
    Sponsor Name:Univ. Klinik f. Anästhesie, Intensivmedizin und Schmerztherapie
    Full Title: Anticoagulation with argatroban and prostacyclin compared to unfractionated heparin and prostacyclin during continous venovenous haemodialfiltation: a crossover trial
    Medical condition: Anticoagulation with argatroban and prostacyclin compared to unfractionated heparin and prostacyclin during continous venovenous haemodiafiltarion: a crossover trial
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-004863-29 Sponsor Protocol Number: 1M Start Date*: 2013-02-18
    Sponsor Name:University Hospitals Leuven (Gasthuisberg) [...]
    1. University Hospitals Leuven (Gasthuisberg)
    2. agentschap innoveren en ondernemen
    Full Title: Direct thrombin inhibitors versus low molecular weight heparins as thromboprophylaxis in Staphylococcus aureus bacteraemia. A prospective randomized controlled academic single-centre feasibility st...
    Medical condition: staphylococcus aureus bacteraemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-000487-23 Sponsor Protocol Number: ArgHeR Start Date*: 2012-05-18
    Sponsor Name:Medizinische Universität Innsbruck / Univ.-Klinik für Allgemeine und Chirurgische Intensivmedizin
    Full Title: A pilot trial to assess the efficacy of Argatroban (Argatra®) in critically ill patients with heparin resistance
    Medical condition: Heparin resistance in critically ill patients with the need of prophylactic anticoagulation
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004865 10036896 Prophylactic procedures NEC HLT
    18.1 100000004865 10036893 Prophylactic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2008-000730-42 Sponsor Protocol Number: ARG-E07 Start Date*: 2009-01-09
    Sponsor Name:Mitsubishi Tanabe Pharma Corporation
    Full Title: An open-label, multi-centre, clinical study to collect information on the clinical use of argatroban in patients with heparin induced thrombocytopenia (HIT) Type II who require parenteral antithrom...
    Medical condition: Heparin induced thrombocytopenia (HIT) Type II
    Disease: Version SOC Term Classification Code Term Level
    9.1 10048672 Heparin-induced thrombocytopenia type II LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2004-001674-80 Sponsor Protocol Number: ARG-E04 Start Date*: 2005-06-13
    Sponsor Name:Mitsubishi Pharma Corporation
    Full Title: A Randomised, Open, Parallel Group, Multicentre Study to Examine the Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Combination with Clopidogrel and Aspirin in Patients u...
    Medical condition: Stable coronary artery disease (CAD) or unstable angina (troponin negative, i.e. within the normal range for the study site) with low to moderate anatomic risk and a requirement for elective percut...
    Disease: Version SOC Term Classification Code Term Level
    7.1 10011078 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2018-002473-21 Sponsor Protocol Number: ERGCR-18-ORGHIT-001 Start Date*: 2019-03-05
    Sponsor Name:Aspen Global Incorporated
    Full Title: An Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study to Evaluate the Safety and Efficacy of Danaparoid vs Argatroban in Treatment of Subjects with Acute HIT (HITSOVA study)
    Medical condition: Acute Heparin-induced Thrombocytopenia (HIT)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10062506 Heparin-induced thrombocytopenia PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FR (Prematurely Ended) CZ (Prematurely Ended) PL (Completed) ES (Prematurely Ended) HR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-003122-28 Sponsor Protocol Number: ArgLepi-2006 Start Date*: 2008-12-19
    Sponsor Name:Heinrich-Heine-Universität Düsseldorf
    Full Title: Argatroban versus Lepirudin in Critically Ill Patients
    Medical condition: Critically ill patients are usually treated with heparin for anticoagulation. A serious complication of heparin therapy is heparin-induced thrombocytopenia type II (HIT). Patients with HIT have t...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10062506 Heparin-induced thrombocytopenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-006611-23 Sponsor Protocol Number: MO21609 Start Date*: 2008-10-27
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Open-label, single-arm, phase II study of bevacizumab (AVASTIN®) in combination with low-dose interferon as first-line treatment of nephrectomised patients with metastatic clear cell renal cell car...
    Medical condition: Metastatic renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050513 Metastatic renal cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) LT (Completed) CZ (Completed) NL (Completed) PT (Completed) GB (Completed) FI (Completed) SE (Completed) DE (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000789-53 Sponsor Protocol Number: VWFC-ECMO Start Date*: 2017-03-09
    Sponsor Name:Medizinische Universität Innsbruck / Univ.-Klinik für Allgemeine und Chirurgische Intensivmedizin
    Full Title: A pilot trial to investigate the administration of von Willebrand factor concentrate (Willfact®, LFB France) in adult patients during extracorporeal membrane oxygenation
    Medical condition: Von Willebrand Disease (VWD)
    Disease: Version SOC Term Classification Code Term Level
    19.1 10005329 - Blood and lymphatic system disorders 10069495 Acquired Von Willebrand's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003036-37 Sponsor Protocol Number: ECMO-vWFC Start Date*: 2017-10-27
    Sponsor Name:Tirol Kliniken GmbH
    Full Title: A double-blind, placebo-controlled pilot trial to investigate the administration of von Willebrand factor concentrate (Willfact®, LFB France) in adult patients during extracorporeal membrane oxygen...
    Medical condition: Von Willebrand Disease (VWD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10069495 Acquired Von Willebrand's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-000565-32 Sponsor Protocol Number: PRIDE Start Date*: 2023-04-27
    Sponsor Name:Klinikum der Universität München
    Full Title: PRIDE: A phase II a, open-label, multicenter study of radiochemotherapy with isotoxic dose escalation and protective VEGF inhibition using bevacizumab in the treatment of patients with first diagno...
    Medical condition: Glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-010390-21 Sponsor Protocol Number: ML21965 Start Date*: 2010-02-10
    Sponsor Name:Roche Pharma AG
    Full Title: A randomized, open-label, multi-center Phase II trial of bevacizumab and radiotherapy fol-lowed by bevacizumab and irinotecan vs. temozolomide and radiotherapy followed by temo-zolomide monotherapy...
    Medical condition: Glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 04 08:42:05 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA